ReviewFrontiers in pharmacology2025
Unveiling the therapeutic potential of berberine: its therapeutic role and molecular mechanisms in kidney diseases.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- TCM-based natural products in type 2 diabetes: a comprehensive review of bioactive compounds and molecular mechanisms.Molecular diversity · 2026Review
- Exosomal miR-145-5p from BMSCs alleviates AKI-induced renal fibrosis via KLHL12/KHSRP-mediated m6A-dependent repression of FLI-1.Cell biology and toxicology · 2026Article
- Polyphenol-Rich Wild Fruits of the Indian Himalayas as a Potential Nutraceutical Candidate for the Management of Endometriosis: A Review.Foods (Basel, Switzerland) · 2026Review
- Multidimensional mechanisms of natural products in modulating metabolic dysfunction-associated kidney disease: recent advances and future perspectives.Frontiers in pharmacology · 2026Review
- Inflammatory bowel disease and renal disorders: from clinical associations to shared mechanisms and management strategies.Frontiers in immunology · 2026Review
- Article
- Nephroprotective effects ofAnnals of medicine and surgery (2012) · 2025Article
- Berberine alleviates respiratory syncytial virus (RSV)-induced pediatric bronchiolitis and fibrosis via suppressing the HMGB1/TLR4/NF-κB pathway.Microbiology spectrum · 2025Article
- Inorganic Nanoparticles Containing Plant-Derived Compounds for Kidney Treatment.Bioinorganic chemistry and applications · 2025Review
- Natural products for intervertebral disc degeneration: mechanistic insights and therapeutic potentials.Frontiers in pharmacology · 2025Review
- Advances in Traditional Chinese Medicine for the treatment of hyperuricemia and associated diseases: pathogenesis, mechanisms, and future directions.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (BBR) is a pentacyclic benzylisoquinoline alkaloid widely distributed across various medicinal plants. Recent studies have demonstrated that berberine possesses a broad spectrum of pharmacological activities, including not only antioxidant properties but also the ability to lower blood glucose, modulate lipid profiles, and mitigate inflammation. These findings suggest that berberine holds significant potential as a therapeutic agent for renal diseases, highlighting its substantial research value. Moreover, when administered orally, berberine has been shown to exhibit a wide therapeutic safety margin. Several studies have identified berberine's renoprotective effects across a range of kidney disorders, including diabetic nephropathy, renal fibrosis, renal aging, kidney toxicity induced by chemotherapy and antibiotics. These properties underscore berberine's evolving therapeutic potential for both acute kidney injury (AKI) and chronic kidney disease (CKD). In summary, the research discussed in this article provides a comprehensive overview of the renoprotective effects of BBR and elucidates the molecular mechanisms underlying its therapeutic potential in the treatment of various renal disease. Furthermore, the article underscores the significance of berberine as a promising therapeutic agent for the treatment of kidney disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.